BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.
about
Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisThe GIST of targeted therapy for malignant melanomaTargeted therapies in development for non-small cell lung cancerProspects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderlyMolecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanomaKIT Mutation and Loss of 14q May Be Sufficient for the Development of Clinically Symptomatic Very Low-Risk GIST.The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS)BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumorsMitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinibAn overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).GISTogram: a graphic presentation of the growing GIST complexity.Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase.Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy.BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors.Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.P16 overexpression in BRAF-mutated gastrointestinal stromal tumors.Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.SETD2 histone modifier loss in aggressive GI stromal tumours.Current research and treatment for gastrointestinal stromal tumors.No KRAS mutations found in gastrointestinal stromal tumors (GISTs): molecular genetic study of 514 cases.ETV1-Positive Cells Give Rise to BRAFV600E -Mutant Gastrointestinal Stromal Tumors.Emerging drugs for the treatment of gastrointestinal stromal tumour.New targets and therapies for gastrointestinal stromal tumors.What is New in Gastrointestinal Stromal Tumor?A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy.Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-mutated gastrointestinal stromal tumors.Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
P2860
Q26800005-B5961DF4-FF14-4F46-BDF1-63536DE3C3A7Q26827092-40CB3C6D-3C67-4891-B3C9-956F937B198AQ27022852-46073AD4-59A7-4C47-BC28-87F26756F54AQ27025344-8E88B9FD-F9F0-4354-959C-C5B76A6A52A7Q33802730-2DF11385-B3BE-4A30-B09C-B6B5FDDC5802Q33895608-E93C5C02-F009-48B8-8053-B2A82EF6188BQ34662717-FE52456A-D41E-4CA6-B182-2C5AEED5514AQ35671824-1E498ABE-78BB-45F4-9376-6F2483074F5AQ36045385-F287CE7F-039C-45AC-961B-5A0027E15F3DQ36509363-8105EB92-AF1C-4464-9023-AF0032989E03Q36561734-A3CF29E9-44FE-4759-BBDB-2FF89CE754E5Q36962548-25CC930B-9079-406D-B249-E528A2E66214Q37051546-C7354392-CE92-4C3B-8914-0DF2CC8684E8Q37327430-657F9734-740D-4097-BDB7-070495119197Q37420174-D3E8E78C-C6A3-4130-B4EA-6FCD37A0247EQ37496876-34DAB609-FADE-497C-8DD7-EC8576ED3CF3Q37520240-CE1186FA-DF8C-422A-8A64-E8C1C3810BD5Q38119931-EF7CCFA7-6130-4565-BC0D-C5239F511B51Q38131403-10D165CF-B732-4A9D-B504-73616A6C2F6DQ38151827-502DEF3D-1A6D-412C-AFB6-9A5FD9E9AB0FQ38268165-837E2F8F-7C78-467F-924A-335EE547BB47Q38399838-F489992A-3588-406F-B5A5-9AEAA959BCF9Q38569221-03E9A122-175E-4F40-ABB0-3B73F284233EQ38730182-45090BBC-B9F4-4BE3-ABA6-7DC0B4D0D578Q38823874-5A20F491-DD48-48EA-9DA3-5F19E91A1F35Q38925022-0CB78FD4-E18F-4D1E-9FB2-1B5ABA6C3953Q39052440-6EEEBF44-8A70-46B2-A31C-3DF275B87077Q39988198-2F6CFF22-C1D8-4A8C-B8EB-289E0A18F850Q40076921-12686247-3732-43DC-8C7B-DDFEF6EF95B1Q40575285-70D78DA5-4004-4727-9DCF-F9E7F039D392Q42337115-D62CD34D-3462-4F82-87EC-E619F2C399B6Q43506385-611565B4-879B-4F7B-8443-D16DE43F1BE0Q46050114-75F33E22-5170-4C18-B8E0-5BEF5D5C22FAQ47355982-D8C91069-76F1-4D49-ACB7-66FED805E310Q47432725-B2583E8B-582B-4865-A7B9-217271BC2973Q50575961-FAA15633-F2B5-4B85-BBD0-A019C6BCD37EQ52663678-7A555ECB-4227-45F3-8265-27CF7EB93B77Q52724679-9999A650-63F5-422F-9DEE-CDD04D1CAF0BQ52908238-37B3045E-F9F2-4B19-A1CB-61CE733EDA6EQ54112985-BE98B789-F95F-49EC-AEF0-E6A063AF888A
P2860
BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
BRAF mutant gastrointestinal s ...... alysis of acquired resistance.
@en
BRAF mutant gastrointestinal s ...... with BRAF inhibitor dabrafenib
@nl
type
label
BRAF mutant gastrointestinal s ...... alysis of acquired resistance.
@en
BRAF mutant gastrointestinal s ...... with BRAF inhibitor dabrafenib
@nl
prefLabel
BRAF mutant gastrointestinal s ...... alysis of acquired resistance.
@en
BRAF mutant gastrointestinal s ...... with BRAF inhibitor dabrafenib
@nl
P2093
P2860
P356
P1433
P1476
BRAF mutant gastrointestinal s ...... alysis of acquired resistance.
@en
P2093
C Beadling
C C Bastida
G S Falchook
J Patterson
M C Heinrich
R Kurzrock
S C Blackman
P2860
P304
P356
10.18632/ONCOTARGET.864
P407
P577
2013-02-01T00:00:00Z